Partial
Mostly Aligned
Patient Risk:
Low
Summary
Some high-level claims about indication and mechanism match the label excerpt (ED indication; PDE5 inhibitor; NO/cGMP via PDE5). However, several statements are unsupported or mismatched to the provided label text—particularly side effects (back pain, nasal congestion, flushing), onset timing (rapid onset/15 minutes effectiveness), and non-label regulatory/patent/manufacturing assertions—so overall alignment is partial.
Category Scores
Accurate Statements
Avanafil is used to treat erectile dysfunction (ED).
Indications and Usage: “STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males.”
Avanafil is a phosphodiesterase type 5 (PDE5) inhibitor.
Indications and Usage: “STENDRA is a phosphodiesterase 5 (PDE5) inhibitor…”
Avanafil works by increasing blood flow to the penis during sexual stimulation.
Clinical Pharmacology mechanism excerpt: enhances effect of NO by inhibiting PDE5, which is responsible for degradation of cGMP in corpus cavernosum.
Unsupported Statements
Stendra is manufactured by Vivus Pharmaceuticals.
No manufacturing/manufacturer information is present in the provided label excerpts.
Generic drugs are chemically identical to their brand-name counterparts.
No generic-chemical-identity statements are included in the provided label excerpts.
Generic drugs are required to meet the same standards for safety, purity, and effectiveness as brand-name drugs.
No ANDA/generic standards statements are included in the provided label excerpts.
The introduction of generic alternatives typically leads to a significant decrease in drug prices due to increased competition.
No pricing/market-competition statements are included in the provided label excerpts.
In the United States, the patent term for a drug is generally 20 years from the date on which the patent application was filed.
No patent-term/regulatory patent law statements are included in the provided label excerpts.
Various factors can extend or shorten the effective period of market exclusivity, such as patent term extensions to compensate for regulatory review time or patent litigation.
No market-exclusivity/patent litigation effect statements are included in the provided label excerpts.
The primary patents associated with Stendra are expected to expire around 2026.
No patent-expiration information is included in the provided label excerpts.
After the patents protecting Stendra expire, other pharmaceutical companies can manufacture and market generic versions of avanafil.
No patent/generic-market-entry statements are included in the provided label excerpts.
Generic companies can challenge a drug's patents before their official expiration date through a process known as patent litigation.
No patent-challenge/litigation process statements are included in the provided label excerpts.
Patent litigation challenges can sometimes lead to earlier market entry for generic versions if the litigation is successful.
No patent/litigation/early entry statements are included in the provided label excerpts.
Avanafil is similar to sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra).
No comparison-to-other branded PDE5 inhibitors statements are included in the provided label excerpts.
Avanafil is known for its rapid onset of action.
The label excerpt provided specifies dosing timing “as early as approximately 15 minutes before sexual activity,” but does not label/characterize “rapid onset” as a general property.
Some studies suggest avanafil can be effective as quickly as 15 minutes after taking the medication.
The label excerpt provided supports taking as early as approximately 15 minutes before sexual activity, not that it is effective “as quickly as 15 minutes after taking.”
Common side effects of avanafil include back pain.
No specific adverse reaction list (including back pain) is provided in the supplied label excerpts.
Common side effects of avanafil include flushing.
No specific adverse reaction list (including flushing) is provided in the supplied label excerpts.
Common side effects of avanafil include nasal congestion.
No specific adverse reaction list (including nasal congestion) is provided in the supplied label excerpts.
Common side effects of avanafil include headache.
No specific adverse reaction list (including headache) is provided in the supplied label excerpts.
Before a generic version of Stendra can be approved and marketed, the generic manufacturer must submit an Abbreviated New Drug Application (ANDA) to the FDA.
No ANDA regulatory process text is included in the provided label excerpts.
The FDA reviews the ANDA to ensure the generic drug is bioequivalent to the brand-name drug.
No ANDA/bioequivalence regulatory process text is included in the provided label excerpts.
Contradictions
Important Omissions
For dosing-related claims, the label specifies recommended starting dose (100 mg), dose adjustments to 200 mg or 50 mg, maximum once-per-day frequency, and sexual stimulation requirement. The AI response did not include these detailed dosage and administration elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly label-relevant safety-related content in the AI list is largely absent; however, several adverse-reaction and timing statements are unsupported by the provided label excerpts, which could mislead users about common side effects or onset. No contraindication or warning claims were made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are unsupported by the provided label excerpts, especially common adverse reactions, onset/effectiveness timing, and non-label patent/generic/manufacturer/regulatory assertions.
Suggested Improvement
Restrict evaluation/claims to what is explicitly supported in the provided label text (e.g., ED indication; dosing timing “as early as approximately 15 minutes before sexual activity”; PDE5/NO-cGMP mechanism). Remove or qualify unsupported side-effect and general onset statements unless the corresponding adverse reaction and time-to-effect label sections are provided.